If biotechnology was a race, China is catching up fast to its European and US competitors. It has accelerated pharmaceutical development by moving on from low-risk, low-margin contract work in generics, to producing innovative and novel therapy research, especially in the burgeoning field of biologics.
The fundamentals look sound. China is already the world’s second-largest pharma market, after the US, and is expected to be worth about $200bn by 2020. It is backed by ambitious central government policies, and there is plenty of money washing around
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?